Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Amgen

8 shared events · Importance 3 · Last updated Jul 19, 2026

Importance
3
Shared Events
8
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
89
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration characterized the medication recall as Class II and is overseeing the recall process initiated by Amgen, ensuring public safety and regulatory compliance.
Amgen: Amgen voluntarily recalled nearly one million bottles of its Corlanor and Sensipar tablets due to the presence of a foreign substance, impacting its product distribution and potentially its reputation, though the health risk is deemed low.
Jun 27, 2026 · 6 articles
60
Regulatory
United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.
Amgen: Competitor with injectable PCSK9 inhibitor Repatha; faces potential market share loss to oral alternative.
Jul 16, 2026 · 93 articles
57
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Amgen: Amgen is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
32
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Amgen: Amgen, a competitor with an approved KRAS G12C inhibitor, may face increased competition but also benefits from validation of the RAS-targeting approach.
Aug 26, 2026 · 92 articles
28
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> (FDA) is the regulatory body reviewing Alvogen's resubmitted applications for AVT05 and AVT06. Their decision will determine the market entry of these biosimilars in the United States>>>.
Amgen: Amgen>>> owns the trademarks for Prolia and Xgeva, the reference products for Alvogen>>>'s AVT03 biosimilar. While not directly related to the current resubmissions, it highlights the competitive landscape Alvogen>>> operates in.
Jun 04, 2026 · 10 articles
28
Regulatory
United States — Food and Drug Administration: The FDA granted Fast Track designation to Varseta-M, facilitating its development and review for a serious condition with unmet medical need.
Amgen: Amgen is a strategic collaborator with CytomX, but this event does not directly affect Amgen's operations or financials.
Aug 27, 2026 · 6 articles
0
Regulatory
May 08, 2026 · 6 articles
0
Business
Apr 23, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Amgen interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.